Cargando…
Endpoints used in phase III randomized controlled trials of treatment options for COVID-19
Autores principales: | Desai, Aakash, Gyawali, Bishal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265861/ https://www.ncbi.nlm.nih.gov/pubmed/32632415 http://dx.doi.org/10.1016/j.eclinm.2020.100403 |
Ejemplares similares
-
Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions
por: Desai, Aakash, et al.
Publicado: (2020) -
Fall in US cancer death rates: Time to pop the champagne?
por: Desai, Aakash, et al.
Publicado: (2020) -
Clinical Trial End Points in Severe COVID-19
por: Desai, Aakash, et al.
Publicado: (2020) -
Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis
por: Desai, Aakash, et al.
Publicado: (2020) -
Me, Too
por: Gyawali, Bishal
Publicado: (2016)